Pretreatment serum beta 2-microglobulin in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Chemistry

Background:

• Multiple myeloma is a plasma cell malignancy.
• Prognostic markers are crucial for treatment planning.

Purpose of the Study:

• To evaluate serum beta 2-microglobulin (S-beta 2m) as a prognostic marker in untreated multiple myeloma.
• To assess the influence of renal function on S-beta 2m levels and their prognostic value.

Main Methods:

• Serum beta 2-microglobulin (S-beta 2m) levels were measured in 121 untreated multiple myeloma patients.
• Correlation analysis was performed between S-beta 2m, clinical stage, and serum creatinine (S-creatinine).
• Survival analysis was conducted based on S-beta 2m levels, with and without adjustment for S-creatinine.

Main Results:

• 82% of patients had elevated S-beta 2m (>3 mg/l).
• Unadjusted S-beta 2m correlated with clinical stage, but not when corrected for S-creatinine.
• Patients with S-beta 2m < 7.6 mg/l had a median survival of 44 months vs. 12 months for those with higher levels.
• Adjusted S-beta 2m cutoff of 6.6 mg/l yielded median survival of 43 months vs. 14 months.

Conclusions:

• Pretreatment S-beta 2m is a valuable predictor of survival in multiple myeloma.
• The relationship between S-beta 2m and S-creatinine requires careful consideration for accurate prognostication.